Bevacizumab biosimilar (Outlook) | Interleukin Related interleukin-related.com

Product Name :
Bevacizumab biosimilar (Outlook)

Search keywords :
Bevacizumab

drugId :
null

Target Vo:
Vascular endothelial growth factor A

Target Vo Short Name :
VEGFA

Moa_Name:
Angiogenesis inhibitors

First Approval Country :
EU

First Approval Date Filter:
2024

Origin Company_Name :
Outlook Therapeutics Inc

Active Company_Name :
Beijing Syntone Biopharma Ltd

Active Indication_Name:
Wet Macular Degeneration

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Enapotamab MedChemExpress
Burosumab References
Cdk2 Antibody: Cdk2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 34 kDa, targeting to Cdk2. It can be used for WB,ICC/IF,IHC-P,IP assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts